Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

In the original publication of this article, [Bruce MG, Bruden D, Hurlburt D et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. The Journal of Infectious Diseases, Volume 214, Issue 1, 1 July 2016, Pages 16–22, https://doi.org/10.1093/infdis/jiv748] it was erroneously reported that participants in this study were given booster doses of the Recombivax HB (Merck) vaccine. However, Engerix-B (GlaxoSmithKline) was the vaccine used for booster doses. The study consent form and the vaccine information statement that was provided to participants refers only to “hepatitis B vaccine” without naming a specific product. Therefore, there is no need to re-contact participants. This error did not adversely impact participants and had no effect on the study results or conclusions.